ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals is a biotechnology company focused on developing oral delivery technologies for therapeutic proteins and vaccines. The company's core platform enables the administration of biologics through capsule form rather than injection, addressing a significant barrier to patient compliance in treatment regimens. Its primary development program is ORMD-0801, an oral insulin capsule currently in Phase III clinical trials for diabetes treatment.

The company also holds license agreements with Oravax Medical to develop and commercialize oral vaccine formulations targeting COVID-19 and related coronavirus variants. This represents a secondary revenue stream opportunity, though commercialization remains dependent on completing clinical development and obtaining regulatory approval.

Founded in 2002 and incorporated in Delaware, Oramed is headquartered in New York. The company operates as a clinical-stage biotechnology firm with limited commercial revenues at present, given its pipeline-dependent business model. Geographic operations include research and development activities in the United States, with collaborative relationships extending internationally through its licensing arrangements.